[144] Surgery Partners, Inc. SEC Filing

Rhea-AI Filing Summary

Surgery Partners, Inc. (SGRY) Form 144 shows an insider notice for the proposed sale of 25,000 shares of common stock to be executed through UBS Financial Services on 09/05/2025 with an aggregate market value listed at $563,700. The filing states those 25,000 shares were acquired the same day, 09/05/2025, as equity compensation from Surgery Partners, Inc., and the payment/transfer is described as an equity option exercise. The filing also lists multiple recent open-market sales by the same individual, Wayne DeVeydt, during August and early September 2025, including transactions of 100,000; 25,000; 11,865; and several 25,000-share sales with disclosed gross proceeds for each trade. The notice includes the standard insider attestation that no undisclosed material adverse information is known.

Positive

• Form 144 filed publicly providing transparency on planned insider sale
• Broker and exact sale details (UBS, date, shares, aggregate market value) are specified
• Acquisition source disclosed as equity compensation and payment method as equity option exercise

Negative

• Multiple recent open-market sales by the same individual in the past three months are reported, which may be viewed negatively by some investors
• Insider selling concentration over a short period could increase share supply pressure

Insights

Securities Analyst

TL;DR Insider has scheduled a 25,000-share sale after exercising options; multiple recent sales by the same person are disclosed.

The filing documents a routine Rule 144 notice for sale of common shares that were immediately acquired via equity option exercise on the same date as the proposed sale. The use of UBS as broker and clear per-trade gross proceeds for prior sales enhances transparency. From a market-impact perspective, recent concentrated sales by one insider can increase supply pressure in the short term, but the filing itself provides procedural compliance rather than operational insight into the company.

Corporate Governance Expert

TL;DR Disclosure is procedurally complete; multiple insider transactions warrant attention but do not alone indicate wrongdoing.

The Form 144 includes required information about acquisition source (equity compensation) and payment method (option exercise), which supports compliance with Rule 144. The repeated sales by the same individual over a short window are material to governance observers because they may reflect personal liquidity events. The filing includes the attestation regarding lack of undisclosed material adverse information, consistent with regulatory expectations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	25000	563700	128209410	09/05/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	09/05/2025	equity compensation	Surgery Partners, Inc.			25000	09/05/2025	equity option exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/21/2025	100000	2299011
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/26/2025	25000	572717
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/27/2025	11865	271756
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/02/2025	25000	562150
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/03/2025	25000	560251
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/04/2025	25000	562756

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for SGRY report?

The Form 144 reports a proposed sale of 25,000 common shares via UBS on 09/05/2025 with an aggregate market value of $563,700, acquired on 09/05/2025 as equity compensation.

Who is the individual associated with the sales?

The filing identifies Wayne DeVeydt as the seller for several recent transactions listed in the form.

Were the shares acquired from the company or purchased in the market?

The 25,000 shares to be sold were acquired as equity compensation from Surgery Partners, Inc. and via equity option exercise dated 09/05/2025.

Does the Form 144 list prior sales by the insider?

Yes. The form lists multiple prior sales in Aug–Sep 2025, including 100,000 shares on 08/21/2025 and several subsequent sales with stated gross proceeds.

Is there any statement about undisclosed material information?

The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.